SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Givaudan S.A. (GVDBF) trades at a trailing P/E of 31.7, forward P/E of 30.3. Trailing earnings yield is 3.16%, forward earnings yield 3.30%. PEG 6.73.
Criteria proven by this page:
- VALUE (60/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
- Forward P/E 30.3 (down from trailing 31.7) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 6.73 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 3.16% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 3.30% as earnings recover.
Overall SharesGrow Score: 64/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GVDBF
Valuation Multiples
P/E (TTM)31.7
Forward P/E30.3
PEG Ratio6.73
Forward PEG6.73
P/B Ratio0.00
P/S Ratio4.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$115.46
Forward EPS (Est.)$120.70
Book Value / Share$0.00
Revenue / Share$805.51
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.16%
Forward Earnings Yield3.30%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$69.34 |
$4.66B |
$644M |
13.8% |
| 2017 |
$77.54 |
$5.05B |
$720M |
14.3% |
| 2018 |
$71.36 |
$5.53B |
$663M |
12% |
| 2019 |
$75.59 |
$6.2B |
$702M |
11.3% |
| 2020 |
$79.96 |
$6.32B |
$743M |
11.8% |
| 2021 |
$88.37 |
$6.68B |
$821M |
12.3% |
| 2022 |
$92.51 |
$7.12B |
$856M |
12% |
| 2023 |
$96.47 |
$6.92B |
$893M |
12.9% |
| 2024 |
$117.63 |
$7.41B |
$1.09B |
14.7% |
| 2025 |
$115.46 |
$7.47B |
$1.07B |
14.3% |
